Cargando…

Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact

BACKGROUND: In a recent article in The Lancet, Protopopoff et al. stated that insecticide resistance must be tackled and concluded that adding the insecticide synergist piperonyl butoxide (PBO) to a bed net with a pyrethroid as principal insecticide might be a part of the response. MAIN TEXT: The st...

Descripción completa

Detalles Bibliográficos
Autor principal: Skovmand, Ole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271413/
https://www.ncbi.nlm.nih.gov/pubmed/30501617
http://dx.doi.org/10.1186/s12936-018-2596-7
_version_ 1783376923263500288
author Skovmand, Ole
author_facet Skovmand, Ole
author_sort Skovmand, Ole
collection PubMed
description BACKGROUND: In a recent article in The Lancet, Protopopoff et al. stated that insecticide resistance must be tackled and concluded that adding the insecticide synergist piperonyl butoxide (PBO) to a bed net with a pyrethroid as principal insecticide might be a part of the response. MAIN TEXT: The study in Tanzania compares malaria prevalence between users of two different nets with the principal insecticide permethrin: Olyset and Olyset Plus (Olyset+), the latter also holding the synergist molecule PBO, the first not. The article is based on randomized cluster trial of very high quality, but Olyset+ exposes much more permethrin at the surface so the higher efficacy may not be because of the added PBO. CONCLUSION: Data published by the World Health Organization (WHO) when evaluating Olyset+ as well of the study of Protopopoff et al. showed that much more permethrin is available on the surface of Olyset+ than on the surface of Olyset and the relatively small and rapidly dwindling dosage of PBO may have nothing to do with the superior effect of Olyset+. The WHO should not change politics for “PBO nets” based on this study alone.
format Online
Article
Text
id pubmed-6271413
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62714132018-12-05 Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact Skovmand, Ole Malar J Opinion BACKGROUND: In a recent article in The Lancet, Protopopoff et al. stated that insecticide resistance must be tackled and concluded that adding the insecticide synergist piperonyl butoxide (PBO) to a bed net with a pyrethroid as principal insecticide might be a part of the response. MAIN TEXT: The study in Tanzania compares malaria prevalence between users of two different nets with the principal insecticide permethrin: Olyset and Olyset Plus (Olyset+), the latter also holding the synergist molecule PBO, the first not. The article is based on randomized cluster trial of very high quality, but Olyset+ exposes much more permethrin at the surface so the higher efficacy may not be because of the added PBO. CONCLUSION: Data published by the World Health Organization (WHO) when evaluating Olyset+ as well of the study of Protopopoff et al. showed that much more permethrin is available on the surface of Olyset+ than on the surface of Olyset and the relatively small and rapidly dwindling dosage of PBO may have nothing to do with the superior effect of Olyset+. The WHO should not change politics for “PBO nets” based on this study alone. BioMed Central 2018-11-30 /pmc/articles/PMC6271413/ /pubmed/30501617 http://dx.doi.org/10.1186/s12936-018-2596-7 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Opinion
Skovmand, Ole
Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact
title Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact
title_full Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact
title_fullStr Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact
title_full_unstemmed Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact
title_short Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact
title_sort comparing the un-comparable: olyset plus and olyset, different malaria impact
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271413/
https://www.ncbi.nlm.nih.gov/pubmed/30501617
http://dx.doi.org/10.1186/s12936-018-2596-7
work_keys_str_mv AT skovmandole comparingtheuncomparableolysetplusandolysetdifferentmalariaimpact